Literature DB >> 11521192

Independent control of cell survival by Raf-1 and Bcl-2 at the mitochondria.

J Zhong1, J Troppmair, U R Rapp.   

Abstract

Bcl-2 family proteins play a critical role in the regulation of cell survival by controlling the activation of the cell death executing caspase machinery. Recent work demonstrated that they also provide a link between growth factor signaling and cell survival control. Raf-1 has been identified initially as an essential component of the mitogenic Ras-Raf-MEK-ERK cascade. However, expression of oncogenic Raf-1 also efficiently suppresses apoptotic cell death. This process requires mitochondrial translocation of Raf-1 which can be achieved either by co-expression of the anti-apoptotic protein Bcl-2 or by fusion with the transmembrane domain of the yeast outer mitochondrial membrane protein Mas 70p. It is currently unclear how mitochondrial Raf-1 prevents apoptosis. One possible mechanism involves the phosphorylation of the pro-apoptotic protein Bad resulting in the restoration of Bcl-2 function. Alternatively, the role of Bcl-2 could be limited to the mitochondrial translocation of Raf-1 and survival signaling by Raf-1 is Bcl-2 independent. To test for the mutual requirement of Raf-1 and Bcl-2 in apoptosis suppression the individual proteins were singly tested for survival activity in a genetic background which precludes the expression of the other. The results obtained in these studies demonstrate that ablation of Raf-1 or Bcl-2 expression in fibroblast cells significantly increases the sensitivity towards doxorubicin induced cell death. Reversion of the mutant phenotype could be achieved in either case by introducing a functional bcl-2 gene or a mitochondria targeted version of oncogenic Raf-1, demonstrating that each protein by itself is sufficient to confer protection. Our data thus suggest the existence of two separate pathways of survival signaling at the mitochondria controlled either by Bcl-2 or by Raf-1.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11521192     DOI: 10.1038/sj.onc.1204614

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  9 in total

1.  Cortical migration defects in mice expressing A-RAF from the B-RAF locus.

Authors:  Guadalupe Camarero; Oleg Yu Tyrsin; Chaomei Xiang; Verena Pfeiffer; Sandra Pleiser; Stefan Wiese; Rudolf Götz; Ulf R Rapp
Journal:  Mol Cell Biol       Date:  2006-10       Impact factor: 4.272

2.  Localization of GRP78 to mitochondria under the unfolded protein response.

Authors:  Fang-Chun Sun; Shou Wei; Chia-Wei Li; Yuo-Sheng Chang; Chih-Chung Chao; Yiu-Kay Lai
Journal:  Biochem J       Date:  2006-05-15       Impact factor: 3.857

3.  Raf family kinases: old dogs have learned new tricks.

Authors:  David Matallanas; Marc Birtwistle; David Romano; Armin Zebisch; Jens Rauch; Alexander von Kriegsheim; Walter Kolch
Journal:  Genes Cancer       Date:  2011-03

4.  Interactions between Ras1, dMyc, and dPI3K signaling in the developing Drosophila wing.

Authors:  David A Prober; Bruce A Edgar
Journal:  Genes Dev       Date:  2002-09-01       Impact factor: 11.361

5.  Survival signaling by C-RAF: mitochondrial reactive oxygen species and Ca2+ are critical targets.

Authors:  Andrey V Kuznetsov; Julija Smigelskaite; Christine Doblander; Manickam Janakiraman; Martin Hermann; Martin Wurm; Stefan F Scheidl; Robert Sucher; Andrea Deutschmann; Jakob Troppmair
Journal:  Mol Cell Biol       Date:  2008-01-22       Impact factor: 4.272

6.  Inhibitors of Ras/Raf-1 interaction identified by two-hybrid screening revert Ras-dependent transformation phenotypes in human cancer cells.

Authors:  Juran Kato-Stankiewicz; Irina Hakimi; Gang Zhi; Jie Zhang; Ilya Serebriiskii; Lea Guo; Hironori Edamatsu; Hiroshi Koide; Sanjay Menon; Robert Eckl; Sukumar Sakamuri; Yingchun Lu; Quin-Zene Chen; Seema Agarwal; William R Baumbach; Erica A Golemis; Fuyuhiko Tamanoi; Vladimir Khazak
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-21       Impact factor: 11.205

7.  Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours.

Authors:  A Awada; A Hendlisz; T Gil; S Bartholomeus; M Mano; D de Valeriola; D Strumberg; E Brendel; C G Haase; B Schwartz; M Piccart
Journal:  Br J Cancer       Date:  2005-05-23       Impact factor: 7.640

8.  Regulation of cellular proliferation, differentiation and cell death by activated Raf.

Authors:  Gerald Thiel; Myriam Ekici; Oliver G Rössler
Journal:  Cell Commun Signal       Date:  2009-04-21       Impact factor: 5.712

9.  Negative regulation of mitochondrial VDAC channels by C-Raf kinase.

Authors:  Véronique Le Mellay; Jakob Troppmair; Roland Benz; Ulf R Rapp
Journal:  BMC Cell Biol       Date:  2002-06-12       Impact factor: 4.241

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.